Kyle Landskroner

Effect of Cyclosporine and Rifampin on the Pharmacokinetics of Macitentan, a Tissue-Targeting Dual Endothelin Receptor Antagonist

Shirin Bruderer, Päivi Äänismaa, Marie‐Claude Homery et al. · The AAPS Journal · 2011 · 68 citations · Full text

Molecular Pharmacology, Hypertension, Multiple-dose Macitentan +14

Comparison of Macitentan and Bosentan on Right Ventricular Remodeling in a Rat Model of Non-vasoreactive Pulmonary Hypertension

Marc Iglarz, Kyle Landskroner, Yasmina Bauer et al. · Journal of Cardiovascular Pharmacology · 2015 · 37 citations · Full text

Thromboelastography measurements of whole blood from factor VIII‐deficient mice supplemented with rFVIII

Kyle Landskroner, Neil C. Olson, Gary Jesmok · Haemophilia · 2005 · 19 citations

Clot Formation, Immunology, Pathology +18

Cross-Species Pharmacologic Evaluation of Plasmin as a Direct-Acting Thrombolytic Agent: Ex Vivo Evaluation for Large Animal Model Development

Kyle Landskroner, Neil C. Olson, Gary Jesmok · Journal of Vascular and Interventional Radiology · 2005 · 16 citations

Cross-species Pharmacologic Evaluation, Thrombosis, Thrombopoiesis +9

Optimization Of Tissue Targeting Properties Of Macitentan, A New Dual Endothelin Receptor Antagonist, Improves Its Efficacy In A Rat Model Of Pulmonary Fibrosis Associated With Pulmonary Arterial Hypertension

Marc Iglarz, Kyle Landskroner, Markus Rey et al. · 2011 · 16 citations

A Rat Model, Antifibrotic Therapy, Pulmonary Arterial Hypertension +15